L-DOPA-13C6

L-DOPA-13C6 is the 13C-labled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

Product Specifications

CAS Number

[201417-12-1]

Product Name Alternative

Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6

UNSPSC

12352005

Target

Dopamine Receptor; Endogenous Metabolite

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/l-dopa-13c6.html

Purity

98.0

Solubility

10 mM in DMSO

Smiles

OC([C@@H](N)C[13C]1=[13CH][13C](O)=[13C]([13CH]=[13CH]1)O)=O

Molecular Formula

C3 13C6H11NO4

Molecular Weight

203.14

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38 (12) :2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 200814 (4) :273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 310:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 154 (2) :330-5.